Dan Zandberg
Clinical trials sponsored by Dan Zandberg, explained in plain language.
-
Triple threat: vaccine, immunotherapy, and chemo join forces against HPV-Linked cancer
Disease control OngoingThis study is for people with a type of head and neck cancer caused by HPV-16 that is considered intermediate risk. The goal is to see if adding an HPV vaccine (ISA101b) and an immunotherapy drug (pembrolizumab) to standard chemoradiation can help keep the cancer from coming back…
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC
-
New combo therapy aims to shrink tough tumors
Disease control OngoingThis study tests a new drug (ARRY-614) combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds a safe dose, and the second part checks if the combinat…
Phase: PHASE1, PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC